BioXcel Therapeutics Inc (NASDAQ: BTAI) on Monday, plunged -6.83% from the previous trading day, before settling in for the closing price of $0.39. Within the past 52 weeks, BTAI’s price has moved between $0.30 and $4.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 53.60% over the last five years. The company achieved an average annual earnings per share of 72.25%. With a float of $41.10 million, this company’s outstanding shares have now reached $42.46 million.
The firm has a total of 74 workers. Let’s measure their productivity. In terms of profitability, gross margin is 4.13%, operating margin of -3295.61%, and the pretax margin is -3119.33%.
BioXcel Therapeutics Inc (BTAI) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of BioXcel Therapeutics Inc is 17.18%, while institutional ownership is 17.38%. The most recent insider transaction that took place on Dec 16 ’24, was worth 58. In this transaction an insider of this company sold 165 shares at a rate of $0.35, taking the stock ownership to the 19,957 shares. Before that another transaction happened on Dec 16 ’24, when Company’s CEO and President sold 3,117 for $0.36, making the entire transaction worth $1,131. This insider now owns 59,605 shares in total.
BioXcel Therapeutics Inc (BTAI) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 72.25% per share during the next fiscal year.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators
BioXcel Therapeutics Inc (BTAI) is currently performing well based on its current performance indicators. A quick ratio of 1.81 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.15, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -1.56 in one year’s time.
Technical Analysis of BioXcel Therapeutics Inc (BTAI)
Analysing the last 5-days average volume posted by the [BioXcel Therapeutics Inc, BTAI], we can find that recorded value of 1.19 million was better than the volume posted last year of 0.84 million. As of the previous 9 days, the stock’s Stochastic %D was 41.02%. Additionally, its Average True Range was 0.06.
During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 10.03%, which indicates a significant decrease from 30.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 91.70% in the past 14 days, which was lower than the 99.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5173, while its 200-day Moving Average is $1.2328. Now, the first resistance to watch is $0.4079. This is followed by the second major resistance level at $0.4490. The third major resistance level sits at $0.4779. If the price goes on to break the first support level at $0.3379, it is likely to go to the next support level at $0.3090. Now, if the price goes above the second support level, the third support stands at $0.2679.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats
Market capitalization of the company is 18.21 million based on 42,748K outstanding shares. Right now, sales total 1,380 K and income totals -179,050 K. The company made 210 K in profit during its latest quarter, and -13,650 K in sales during its previous quarter.
